Age, Ki-67, Nodal pCR and overall survival following Neoadjuvant Chemotherapy for Node Positive ER+/Her2-Breast Cancer

被引：0
|
作者：
Moldoveanu, Dan
Goetz, Matthew P.
Hoskin, Tanya L.
Day, Courtney N.
Boughey, Judy C.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P6-01-22
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-01-22
引用
收藏
页数：3
相关论文
共 50 条
  • [21] PTCH1 and CTNNB1 emerge as pivotal predictors of resistance to neoadjuvant chemotherapy in ER+/HER2-breast cancer
    Ozcan, Gulnihal
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [22] Adjuvant chemotherapy is associated with an overall survival benefit regardless of age in ER+/HER2-breast cancer pts with 1-3 positive nodes and oncotype DX recurrence score 20 to 25: an NCDB analysis
    Stabellini, Nickolas
    Cao, Lifen
    Towe, Christopher W.
    Luo, Xun
    Amin, Amanda L.
    Montero, Alberto J.
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [23] ER, PR, Her2, and Ki-67 Expression in Male and Female Breast Cancer
    Lockyer, M. G.
    Martinez-Blanco, E.
    Verstovsek, G.
    Bedrosian, I.
    Albarracin, C.
    Rosen, D.
    [J]. MODERN PATHOLOGY, 2013, 26 : 54A - 55A
  • [24] ER, PR, Her2, and Ki-67 Expression in Male and Female Breast Cancer
    Lockyer, M. G.
    Martinez-Blanco, E.
    Verstovsek, G.
    Bedrosian, I.
    Albarracin, C.
    Rosen, D.
    [J]. LABORATORY INVESTIGATION, 2013, 93 : 54A - 55A
  • [25] Proliferation Determined by Ki-67 Defines Different Pathologic Response to Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer
    Sanchez-Munoz, Alfonso
    Navarro-Perez, Victor
    Plata-Fernandez, Yessica
    Santonja, Angela
    Moreno, Ignacio
    Ribelles, Nuria
    Alba, Emilio
    [J]. CLINICAL BREAST CANCER, 2015, 15 (05) : 343 - 347
  • [26] Impact of hormone receptor, HER2, and Ki-67 status conversions on survival after neoadjuvant chemotherapy in breast cancer patients: a retrospective study
    Chen, Yuhai
    Liu, Xiaoyan
    Yu, Keda
    Sun, Xiangyu
    Xu, Shouping
    Qiu, Pengfei
    Lv, Zhidong
    Zhang, Xinwen
    Guo, Ayao
    Xu, Yingying
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (02)
  • [27] Effect of adjuvant chemotherapy in patients with ER+/HER2-breast cancer, assessed by propensity score matching: significance of nuclear grade and nodal status
    Tanaka, Natsuko
    Hirano, Akira
    Hattori, Akinori
    Ogura, Kaoru
    Kamimura, Mari
    Inoue, Hiroaki
    Yukawa, Hiroko
    Sakaguchi, Shiho
    Matsuoka, Aya
    Kodera, Asaka
    Shimizu, Tadao
    [J]. BREAST CANCER, 2021, 28 (01) : 40 - 47
  • [28] Evaluation of ER, PgR, HER2 and Ki67 as predictors of response to neoadjuvant chemotherapy for operable breast cancer
    Burcombe, RJ
    Makris, A
    Richman, PI
    Pittam, M
    Daley, F
    Nobe, S
    Wilson, GD
    [J]. BRITISH JOURNAL OF CANCER, 2001, 85 : 50 - 50
  • [29] Prognostic value of breast MRI characteristics before and during neoadjuvant endocrine therapy in patients with ER+/HER2-breast cancer
    Ragusi, Max A. A.
    Winter-Warnars, Gonneke A. O.
    Wesseling, Jelle
    Linn, Sabine C.
    Beets-Tan, Regina G.
    van der Velden, Bas H. M.
    Elias, Sjoerd G.
    Gilhuijs, Kenneth G. A.
    Loo, Claudette E.
    [J]. BRITISH JOURNAL OF RADIOLOGY, 2021, 94 (1123):
  • [30] Neoadjuvant Chemotherapy and Nodal Response Rates in Luminal Breast Cancer: effects of Age and Tumor ki67
    Matar, Regina
    Boughey, Judy C.
    Hoskin, Tanya
    Goetz, Matthew P.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (SUPPL 2) : 338 - 339
12345